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ABSTRACT 
The objectives of this thesis were to assess the validity of the diagnostic 
codes for ankylosing spondylitis and undifferentiated spondyloarthritis in the 
national patient register (study I), and to estimate the prevalence of 
ankylosing spondylitis in Sweden, as well as to compare the prevalence 
according to geographic and demographic factors (study II). Further, to 
compare inflammatory back pain, and perceived health, in different subtypes 
of spondyloarthritis (study III), and to investigate predictive associations 
between perinatal characteristics, and childhood infections, with later 
development of ankylosing spondylitis (study IV and V).  
The diagnoses in the register, were found to have a high validity. The point-
prevalence of ankylosing spondylitis in Sweden, in 2009, was estimated to be 
0.18%, with a higher prevalence associated with a shorter formal education, 
and a higher prevalence in northern Sweden compared to the southern parts. 
Current inflammatory back pain was common across the three subtypes of 
spondyloarthritis analyzed (43% of ankylosing spondylitis, 31% of psoriatic 
arthritis and 39% of other spondyloarthritis) and the groups reported similar 
levels of perceived health. Having older siblings (odds ratio[OR]: 1.23; 95% 
confidence interval[CI]: 1.09-1.39), and hospitalization with respiratory tract 
infections during childhood (OR: 1.24; 95% CI: 1.07-1.44), were associated 
with an increased risk for development of ankylosing spondylitis, and 
appendicitis with a decreased risk (OR: 0.59; 95% CI: 0.41-0.83).  
In conclusion, axial spondyloarthritis is a significant health issue, and early 
life exposures appear to be associated with the disease development. 
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SAMMANFATTNING PÅ SVENSKA 
Spondylartriter är en grupp besläktade reumatiska sjukdomar, som ger 
inflammation i rygg, leder och muskelfästen. När spondylartrit engagerar 
ryggen brukar den benämnas som axial. Den bäst studerade formen av axial 
spondylartrit kallas ankyloserande spondylit och ger ofta karaktäristiska 
skelettförändringar i ryggraden och korsbenslederna. Axial spondylartrit är 
kopplat till en genetisk uppsättning, som kallas HLA-B27, och förekomsten 
av axial spondylartrit i världen följer ganska väl förekomsten av just HLA-
B27, även om andra genetiska riskfaktorer också är kända. Det är troligt att 
även omgivningsfaktorer påverkar risken att insjukna, men detta är relativt 
outforskat. 
Syftet med denna avhandling har varit att utvärdera hur tillförlitliga 
diagnoserna ankyloserande spondylit och odifferentierad spondylartrit är i det 
nationella patientregistret (delarbete I). Därefter beskrivs förekomst av 
ankyloserande spondylit i Sverige, geografisk/demografisk fördelning och 
skillnader mellan kön och åldersgrupper (delarbete II). Vidare jämförs 
förekomst av inflammatorisk ryggsmärta mellan olika typer av spondylartrit, 
samt hur detta återspeglas i självupplevd hälsa (delarbete III). Slutligen 
jämförs fall, som senare i livet utvecklar ankyloserande spondylit, med 
befolkningskontroller, avseende olika särdrag vid födseln och infektioner 
under uppväxten (delarbete IV och V). Studierna grundar sig i huvudsak på 
uppgifter insamlade från nationella och regionala register i Sverige. I 
delarbete III kompletteras detta med en enkät, som skickades till patienter 
med spondylartrit.  
Förekomsten av ankyloserande spondylit i Sverige 2009 beräknades till 
0,18%.  Förekomsten var högre i norra Sverige, jämfört med södra, och även 
högre bland de med en kortare utbildningslängd jämfört med de med en 
längre utbildning. Inflammatorisk ryggsmärta var vanligt bland samtliga av 
de studerade typerna av spondylartrit och de rapporterade liknande själv-
upplevd hälsa. De som utvecklade ankyloserande spondylit hade i en högre 
utsträckning äldre syskon och hade oftare vårdats för luftvägsinfektioner 
under barndomen, jämfört med matchade befolkningskontroller. Blindtarms-
inflammation i barndomen tycktes istället vara kopplat till en lägre risk för att 
utveckla ankyloserande spondylit senare i livet. 
Sammanfattningsvis medför axial spondylartrit en påtaglig hälsopåverkan, 
och infektioner i barndomen tycks vara förknippade med sjukdoms-
utvecklingen.
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1 INTRODUCTION 
 
1.1 Axial Spondyloarthritis 
Spondyloarthritis is the collective term used for a group of related 
inflammatory diseases sharing several features, but also expressing distinct 
differences. Common to the spondyloarthritis diseases is that they tend to 
cause inflammation in the spine and sacroiliac joints, as well as in entheses, 
tendons and peripheral joints(1). The diseases normally classified as 
spondyloarthritis are presented in table 1.  
 The spondyloarthritis diseases and related inflammatory disorders 
 
The group of spondyloarthritis diseases also belong to a wider spectrum of 
inflammatory disorders, which to different degrees appear to share 
similarities in risk factors, inflammatory pathways, and response to 
treatment(2-6). These inflammatory disorders often coexist and spondylo-
arthritis is thus often accompanied by other diseases in the family, most 
frequently psoriasis, inflammatory bowel disease and anterior uveitis (6), but  
other manifestations, such as involvement of the conduction system and 
valves of the heart(7, 8) are also well-known (included in table 1).   
Axial spondyloarthritis is the term used when spondyloarthritis manifests 
with inflammation in the back, and it can include all of the different subtypes 
of spondyloarthritis mentioned above(9). Ankylosing spondylitis is a specific 
subtype of spondyloarthritis, which always includes inflammation in the axial 
skeleton, and it can therefore be considered the prototype of axial spondylo-
arthritis(10). This thesis focuses on axial spondylitis in general, and in 
Spondyloarthritis subtypes Related inflammatory disorders 
Ankylosing spondylitis Inflammatory bowel disease 
Juvenile spondyloarthritis Psoriasis 
Psoriatic arthritis Anterior uveitis 
Arthritis associated with inflammatory bowel disease  Cardiac involvement 
Reactive arthritis  
Undifferentiated spondyloarthritis  
Axial spondyloarthritis 
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particular on ankylosing spondylitis, but it also touches on the other forms of 
spondyloarthritis and the related disorders when appropriate. 
1.2 Classification 
In clinical practice, the diagnoses comprising the spondyloarthritis group are 
often defined through their co-presentation with the other inflammatory 
disorders, such as psoriatic arthritis associated with psoriasis or spondylo-
arthritis associated with inflammatory bowel disease(11). At present this 
approach of classification is complemented, or perhaps rivaled by, the 
strategy of instead categorizing the spondyloarthritis diseases into axial 
spondyloarthritis, predominantly affecting the spine and sacroiliac joints, or 
peripheral spondyloarthritis predominantly affecting joints, entheses or 
tendons in the extremities(12).  
 Frequently used classification criteria for spondyloarthritis. 
 
Both strategies of classification are limited by the diversity within the 
subgroups, the variability of the disease expression, the wide range in disease 
severity and the overlap between the phenotypes. Several different sets of 
classification criteria have been developed, for research purposes, both for 
the whole group of spondyloarthritis, but also for the different subtypes, as 
well as for axial and peripheral spondyloarthritis(12-17), presented in table 2. 
As a result, in contemporary studies, it is not uncommon that several sets of 
classification criteria are included to describe the study population(18, 19). 
An alternative approach, of classifying rheumatic diseases according to 
inflammatory pathways has been suggested(20), but has yet to be developed. 
1.3 Clinical presentation 
In ankylosing spondylitis, the main symptom is chronic back pain, 
originating from inflammation in the sacroiliac joints and the spine(21). The 
pain presents with the characteristic features of so called “inflammatory back 
Classification criteria Spondyloarthritis subtypes 
New York (modified)(13) ankylosing spondylitis 
ESSG(14) spondyloarthritis 
Amor(15) spondyloarthritis 
ASAS(12, 16) axial/peripheral spondyloarthritis 
CASPAR(17) psoriatic arthritis 
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pain”, which includes insidious onset, pain at night, morning stiffness, and 
improvement with exercise(22). In ankylosing spondylitis, over time, the 
inflammation also leads to inflammatory damage and bone formation in the 
sacroiliac joints and spine, which may result in a fusion of the joints and 
vertebrae, giving it a typical appearance some-times referred to as bamboo 
spine(21, 23). The disease onset is usually in the early adult-hood, in about 
80% the first symptoms start before the age of 30 years, and may over time 
lead to marked functional impairment(21).  
In other forms of axial spondyloarthritis the effect on bone destruction and 
bone formation in the spine may be less pronounced, but the symptoms and 
progression can otherwise be similar(10). For the other subtypes of 
spondyloarthritis, such as psoriatic arthritis and arthritis associated with 
inflammatory bowel disease, the degree of axial involvement varies and less 
is known about what determines this and the extent to which it contributes to 
the overall morbidity. 
1.4 Advances in diagnostics 
Since ankylosing spondylitis causes disease specific bone pathology in the 
sacroiliac joints and vertebrae, the introduction of radiographs into clinical 
practice allowed physicians to diagnose the disease more accurately. This 
eventually led to the proposal of classification criteria for the disease in 1963, 
which with only minor changes, the latest from 1984, are still used: The 
modified New York criteria (table 3)(13).  
 The modified New York criteria for ankylosing spondylitis(13). 
 
The modified New York criteria depend on the detection of radiographic 
pathology in the sacroiliac joints. However, the bone pathology that can be 
seen on plain radiographs takes time to develop, which is one of the reasons 
Definitive ankylosing spondylitis if radiological criterion is associated with at least 1 
clinical criteria 
Clinical criteria: 
a) Low back pain and stiffness for more than 3 months which improves with exercise, but 
is not relieved by rest. 
b) Limitation of motion of the lumbar spine in both the sagittal and frontal planes.  
c) Limitation of chest expansion relative to normal values corrected for age and sex. 
Radiologic criterion: 
Sacroiliitis grade ≥2 bilaterally or sacroiliitis grade 3-4 unilaterally. 
Axial spondyloarthritis 
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for the considerable diagnostic delay (e.g. in one study of disease duration the 
average time from the first symptoms to the final diagnosis was 8.8-10.4 
years(24)). This poses problems both in the clinical setting and in research. 
From the patient perspective, relying on traditional radiographs to reveal 
sacroiliitis, before diagnosing ankylosing spondylitis, may not only cause a 
diagnostic delay, but a number of patient may not develop radiographic 
sacroiliitis at all, even after a prolonged time of symptomatic disease(25). In 
a research setting, using the modified New York criteria, also prevents the 
inclusion of early disease phases of ankylosing spondylitis, before 
development of radiographic pathology.  
 During the last decade advances in detection, of sacroiliitis and spine 
inflammation, based on magnetic resonance imaging (MRI) has challenged 
the use of traditional radiographs(26). The advantage of MRI is that it can 
visualize both the typical bone destruction seen on radiographs, but also 
earlier stages of the inflammation, before the bone damage has occurred(26). 
In clinical practice this has offered a means to diagnose axial 
spondyloarthritis at an earlier stage, although not ankylosing spondylitis for 
which radiographic damage is still required. For research purposes, MRI has 
also greatly improved the prospects of detecting and studying early phases of 
axial spondyloarthritis(27).  
  The ASAS-criteria for axial spondyloarthritis(12). To be applied in 
patients with ≥3 months of back pain and age of onset < 45 years. 
 
Table 4 presents the current ASAS-criteria (Assessment of SpondyloArthritis 
international Society) for axial spondyloarthritis(12), which incorporates 
MRI findings. Axial spondyloarthritis, fulfilling the ASAS-criteria for axial 
Axial spondyloarthritis is present if: 
1. Sacroiliitis on imagining (either definitive radiographic sacroiliitis according to the 
modified New York criteria or active inflammation on MRI highly suggestive of 
sacroiliitis) plus ≥1 other of the following spondyloarthritis features 
OR 
2. HLA-B27 plus ≥ 2 other of the following spondyloarthritis features 
inflammatory back pain good response to NSAIDs 
arthritis family history for spondyloarthritis 
enthesitis (heel) HLA-B27 
uveitis elevated C-reactive protein 
dactylitis inflammatory bowel disease 
psoriasis  
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spondyloarthritis, but lacking definitive structural changes in the sacroiliac 
joints, according to the modified New York criteria, is now often called non-
radiographic axial spondyloarthritis(6).  
The exact nature of non-radiographic axial spondyloarthritis, and how it 
relates to the traditional diagnoses of ankylosing spondylitis, and the other 
subtypes of spondyloarthritis, is not entirely determined or globally 
excepted(28). In some studies a progression rate of around 12% over 2 years, 
from non-radiographic axial spondyloarthritis to ankylosing spondylitis has 
been shown(10, 29), although other results have suggested that a substantial 
proportion of patients with non-radiographic axial spondyloarthritis do not 
develop radiographic sacroiliitis even after 15 years of follow-up(25). 
1.5 Treatment 
The basis for treating axial spondyloarthritis consists of physiotherapy and 
exercise, often in combination with non-steroidal anti-inflammatory 
drugs(NSAID)(21). This treatment approach can give a remarkably good 
effect(30), but many patients still fail to achieve an acceptable level of 
disease activity(21). During the last decades, major advances have been made 
in the treatment, mainly due to the introduction of tumor necrosis factor 
(TNF) inhibitors and more recently other targeted biological treatments(31, 
32). But, as we still lack an understanding of the causes of the diseases and 
what mechanisms initiate and uphold the inflammation, there is no curative 
treatment to offer. 
1.6 History and causes 
The characteristic disease expression of ankylosing spondylitis led to an early 
recognition of the disease, and accurate descriptions can be traced back 
through history in different geographical areas(33), and also arguably in 
archeological remains(34, 35). The oldest studied remains in Sweden, with 
probable ankylosing spondylitis, of a man buried in the church ruins of St 
Clemens in the town of Visby (900-1300 AD), exhibits the both the 
characteristic skeletal pathology and the HLA-B27 (human leucocyte antigen 
B27) genotype typically associated with the disease(36). The geographical 
and historical distribution suggests that the pathogenic factors leading to 
ankylosing spondylitis are neither new nor geographically confined.  
The risk of acquiring ankylosing spondylitis is now thought to be 
predominantly genetic. The most studied genotype is HLA-B27, which is 
Axial spondyloarthritis 
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also known to correspond closely to the prevalence of ankylosing spondylitis 
in different populations(37), but a growing number of other genetic 
associations are also being described, such as IL23R (interleukin 23 receptor) 
and ERAP (endoplasmic reticulum aminopeptidase)(2).  
In contrast, the role of environmental risk factors is still obscure and though 
such factors are suspected to be involved in the pathogenesis(38), the 
interplay between genes and environment is poorly understood. Lately, the 
understanding that ambient exposures, such as smoking(39) and 
occupation(40), may be associated with the rate of radiographic progression 
in axial spondyloarthritis has increased. From an epidemiological point of 
view this is of interest, since such observations could also lead to a better 
understanding of risk factors contributing to the disease onset. 
1.7 This thesis  
This thesis describes the prevalence of ankylosing spondylitis in Sweden, and 
compares the prevalence of inflammatory back pain between different 
subtypes of spondyloarthritis, and how this reflects on self-perceived health. 
Further, it also investigates possible non-genetic predictors for development 
of ankylosing spondylitis.  
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2 PREVALENCE  
 
Chronic low back pain is the key feature in axial spondyloarthritis(12). 
However, low back pain is also very common in the general population, with 
studies indicating a 1-month prevalence in the adult population of about one 
third(41, 42), and the 1-year consultation prevalence in southern Sweden has 
been estimated to be close to 4%(43). The prevalence of chronic low back 
pain (lasting more than 3 month) has been estimated to be 10%(44). In a 
primary care setting the prevalence of inflammatory back pain, among 
patients with back pain has been reported to be 15%(45), and axial 
spondyloarthritis (according to the ASAS-criteria) has in one study been 
described in as many as 24% of patients with chronic low back pain(46).  
Having a reliable method for case-identification is a prerequisite in 
prevalence studies, and in the case of axial spondyloarthritis the subjects 
must be distinguished from sufferers of other forms of chronic back pain, in 
the general population. In prevalence studies of ankylosing spondylitis, the 
general approach has been, and still is, to classify the disease according to the 
modified New York criteria(47, 48).  
For axial spondyloarthritis overall, the recently developed ASAS-criteria for 
axial spondyloarthritis have been estimated to have a sensitivity of 82.9% and 
a specificity of 84.4%(49), while the definition used to identify “inflamma-
tory back pain”, within this criteria set, has been estimated to have a 
sensitivity of 79.6% and a specificity of 72.4%(50). The respective sensitivity 
and specificity were determined in the specific setting of patients with 
chronic back pain, and onset before the age of 45 years, referred to 
rheumatology clinics, but the criteria have also been applied in studies with a 
population-based setting(51) and in a primary care setting(52).  
However, since the ASAS-criteria, and the current concept of axial 
spondyloarthritis are rather new, they are not congruent with other 
classification systems frequently used in health care, such as the International 
Classification of Diseases (ICD) issued by the World Health Association 
(WHO)(53). This may pose a problem when identifying subjects with axial 
spondyloarthritis from pre-existing data sources, such as health care registers, 
insurance register and medical records.  
Axial spondyloarthritis 
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In epidemiological studies of ankylosing spondylitis, a number of different 
methods have been used for data collection, which can roughly be sorted into 
two categories. First, identifying cases through existing data sources, such as 
medical records or health care registers. Second, identifying the cases 
through different types of surveys, screening for symptoms or other findings 
compatible with ankylosing spondylitis.  
An example of the first approach is a study from Rochester (USA) in 1979, 
where the cases were identified through the medical records of the Mayo 
clinic(54). An example of the survey-based approach is a French study from 
2005(55), where a random sample was selected from the national telephone 
directory, and subsequently phoned and asked whether they had pain in their 
joints or back, and if affirming this, if they had been given any of a number 
of specified rheumatic/inflammatory disorders. The subjects thus identified 
were then screened more thoroughly through telephone interviews, and if 
needed through further examination. Another example, of the survey 
approach, is a study from Norway in 1985(48), where all men (age 20-54 
years) and women (age 20-49 years) in the municipality of Tromsø, were 
invited to participate in a survey. Those who accepted were sent a 
questionnaire, and from the subjects reporting back pain or back stiffness, a 
random sample was clinically examined. The prevalence estimates 
determined through the examples above are presented in table 5 (page 10).  
2.1 Geographical distribution of ankylosing 
spondylitis 
Much of the variation in the prevalence of ankylosing spondylitis, between 
different ethnical populations and geographical regions, can be explained by 
variations in the HLA-B27 prevalence(37). Globally, a north-south gradient 
for HLA-B27 appears to exist, but also distinct differences between different 
ethnical groups, with a high prevalence among indigenous people in the 
arctic regions of the northern hemisphere, and a low prevalence in the 
southern hemisphere(56).  
Using Scandinavia as an example, the HLA-B27 prevalence of the 
indigenous Sami people in northern Norway has been estimated to be 
24%(57), compared to 16% among non-Sami Norwegians in the same 
area(58) and 17% in the population of northern Sweden(59). In contrast to 
this, in the southern part of Sweden only 10% have HLA-B27(60). 
Corresponding to this, estimates of ankylosing spondylitis in northern 
Norway have indicated a prevalence of 1.1-1.4%(48), and in southern 
Ulf Lindström 
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Sweden of 0.12%(61), although it should be noted that there are considerable 
differences in the methods used to obtain these estimates, in that the first is 
based on a population-based survey (described in the previous section) and 
the second on a regional health care register. 
Geographical differences in HLA-B27 prevalence 
The cause of the north-south gradient of HLA-B27 is not known. HLA type 
A, B and C codes for the major histocompatibility complex (MHC) class I in 
humans, and are instrumental in cell-surface antigen presentation(62). As 
HLA plays a central role in the adaptive immune-system, it has been 
suggested that the geographical differences may be a result of an evolutionary 
pressure from endemic micro-organisms, where certain HLA types could 
give an evolutionary advantage or disadvantage depending on the local 
spectrum of infectious diseases(63, 64).  
One such theory suggests that HLA-B27 prevalence may be associated with 
an evolutionary pressure from the malaria parasite Plasmodium falciparum. 
This theory is based on comparisons of HLA-B27 prevalence and P. 
falciparum prevalence, both on a global level but also within indigenous 
populations in neighboring areas(65). Such a relationship is hard to prove, 
and hitherto data describing the outcome for P. falciparum infection in HLA-
B27 positive individuals appear to be lacking, although one study has 
indicated that HLA-B27 may be overrepresented in patients treated for severe 
P. falciparum malaria(66).  
HLA-B27 has also been associated with differences in the outcome for other 
severe infections. In HIV, it has been demonstrated that HLA-B27 is 
associated with a slower disease progression(67)  and in hepatitis C with a 
more favorable outcome(68). A lower anti-body response to rubella 
vaccination(69) has also been found in HLA-B27 carriers. The relationship 
between HLA-B27, and ankylosing spondylitis on one side, and infections on 
the other side, needs to be further studied. 
2.2 Prevalence of ankylosing spondylitis 
A sample of studies on the prevalence of ankylosing spondylitis in Europe 
and North America are presented in table 5. It can be seen that the prevalence 
estimates vary considerably between the studies, even for studies performed 
in the same population, which is unlikely to be explained only by true 
variations in prevalence. Instead, it is probable some of this variation is due 
to methodology, and in particular the different methods used to identify the 
cases. For example in the 2004 study in north-western Greece, by 
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Alamanos(70), the cases were identified from patients referred to local 
rheumatology clinics, while in the 2010 study by Anagnostopoulos(71), 
indicating a 10-fold higher prevalence in central Greece, a postal 
questionnaire was used for the initial screening of a population sample.  
 A sample of prevalence (%) studies on ankylosing spondylitis. 
 
However, considering the differences in methodology and taking into account 
two recent systematic reviews, arriving at very similar estimates(76, 77), the 
prevalence of ankylosing spondylitis is probably somewhere around 0.2% in 
Europe, but can vary significantly between different populations in this area. 
2.3 Demographic distribution of ankylosing 
spondylitis 
Ankylosing spondylitis has previously been considered a predominantly male 
disease, with accounts of the sex ratio usually in the order of 6:1or more(78). 
In later studies, and in particular in population-based studies, the ratio is often 
less pronounced(54), and in one of the recent systematic reviews the male-
Year First author Region Case identification Prevalence  
North America 
1972 Gofton(72) Canada* males +25 on reserve list 6.7 
1979 Carter(54) USA Mayo clinic records 0.13 
2013 Strand(73) USA rheumatology clinics 0.35 
Europe 
1985 Gran(48)  Norway survey  1.1 - 1.4 
2005 Bakland(74)  Norway rheumatology clinic 0.21 
2011 Haglund(61) Sweden health care register 0.12 
1998 Braun(47)  Germany survey among blood-donors 0.86 
2005 Saraux(55) France survey 0.08 
2013 Costantino(75) France population cohort 0.31 
2004 Alamanos (70) Greece rheumatology clinics 0.03 
2010 Anagnostopoulos(71) Greece postal survey 0.29 
Systematic reviews 
2014 Dean(76) Europe systematic review 0.24 
2015 Stolwijk(77) Europe systematic review  0.25 
*) Haida - Native American tribe 
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female ratio in Europe was 3.8:1(76). In contemporary “early disease” 
cohorts of axial spondyloarthritis a 1:1 ratio is more common(18, 79), which 
is consistent with the belief view that non-radiographic axial spondylo-
arthritis is more common in women(10).  
In studies of ankylosing spondylitis, and spondyloarthritis in general, the 
prevalence normally increases gradually up to an age around 60 years(54, 55) 
and then levels out. The explanation for the increase and plateau is that the 
debut of ankylosing spondylitis occurs early in life, in about 80% before the 
age of 30 years and rarely after the age of 45 years(21),  and since it is a 
chronic disease the prevalence at a specific age equals the cumulative 
incidence. Little is known about other possible demographic factors 
influencing the prevalence of ankylosing spondylitis, such as socioeconomic 
status or occupation. 
2.4 Axial disease in other spondyloarthritis 
subtypes  
In ankylosing spondylitis, and the more recent concept of non-radiographic 
axial spondyloarthritis, an axial component is obligatory for the diagnosis. 
However, the disease activity and clinical expression in axial spondylo-
arthritis can vary over time and with treatment, so that not all individuals will 
have axial symptoms at any given time, and a minority may even go into 
spontaneous remission(80).  
It has been suggested that the prevalence of non-radiographic axial 
spondyloarthritis is likely to be similar to the prevalence of ankylosing 
spondylitis(10, 73), and that ankylosing spondylitis and non-radiographic 
axial spondyloarthritis may be different expressions of the same disease. This 
could be supported by studies showing similar frequencies of extra-articular 
manifestations(9), as well as similar response to treatment(81).  
The other clinical subtypes of spondyloarthritis, such as psoriatic arthritis, 
arthritis associated with inflammatory bowel disease, and reactive arthritis, 
may also have an axial expression, but can manifest without symptoms from 
the back(1). To what degree the other spondyloarthritis subtypes have axial 
disease is less studies, and the results may be influenced by the fact that e.g. 
psoriatic arthritis with sacroiliitis may also correctly be classified as 
ankylosing spondylitis or axial spondyloarthritis, and vice versa, according to 
preference of which set of classification criteria are used.  Prevalence of axial 
disease in the other subtypes are discussed in the following sections. 
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2.4.1 Psoriatic arthritis 
The prevalence of psoriatic arthritis is largely determined by the prevalence 
of cutaneous psoriasis, which in Europe is about 2%(4). The prevalence of 
psoriatic arthritis is less studied than that of cutaneous psoriasis, and reported 
estimates vary significantly. One reason for this is that a number of different 
methods have been used to classify psoriatic arthritis in the studies, 
sometimes based on classification criteria for spondyloarthritis in general 
(such as the ESSG), which may not be optimal for this purpose(82). Another 
reason is that the estimates have been determined either through identifying 
the cases in a normal population or within a population with cutaneous 
psoriasis(82). Both using generic criteria for spondyloarthritis and identifying 
cases within a population with psoriasis may cause errors, since not all 
arthritis coexisting with psoriasis is psoriatic arthritis, and since psoriatic 
arthritis can occur without previous cutaneous psoriasis(83). Hence, the 
described prevalence estimates for psoriatic arthritis, within patients with 
psoriasis, rage from 1-48%(83-86), a variation which is however also 
affected by regional differences and genetic factors.   
Having said that, one population-based, survey in England(87), performed on 
patients with psoriasis identified through a primary care register, estimated a 
prevalence of 13.8% of psoriatic arthritis (according to the CAPAR-
criteria(17)) within the population with psoriasis. Another, large population-
based telephone survey in the US(88) estimated a similar prevalence of 11%, 
and a recent population-based study in southern Sweden (register-based) also 
found a similar prevalence of 17.3% of psoriatic arthritis within a population 
with psoriasis(89). 
The prevalence of axial disease in psoriatic arthritis has been described as 20-
40%, and it has been suggested that it may have a more favorable out-come 
than in ankylosing spondylitis(90). The current CASPAR-classification 
criteria for psoriatic arthritis(17) only include a rather vague definition of 
axial disease, and population based studies are rare. As an example, in a 
comparison of patients with psoriatic arthritis, ankylosing spondylitis and 
undifferentiated spondyloarthritis, at a rheumatology clinic in 2013(91), 49% 
of the patients with psoriatic arthritis reported a history of inflammatory back 
pain, and 22% presented a “high grade” sacroiliitis on radiographs (fulfilling 
the modified New York radiographic criteria). However, the frequencies 
obtained in such a population of patients, at a dedicated spondyloarthritis 
clinic, can not necessarily be generalized to the general population. In another 
example, a population-based study in Greece found a prevalence of psoriatic 
arthritis of 0.17%, in the general population, of which 39.8% had 
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sacroiliitis(92). In another large population-based survey(93) (NHANES), 
17% of the responders, reporting a history of cutaneous psoriasis, also 
fulfilled the Berlin criteria for inflammatory back pain. These latter results 
suggest that axial disease may be more common in psoriasis than previously 
thought, but further studies are needed. 
2.4.2 Spondyloarthritis associated with inflammatory 
bowel disease 
Inflammatory bowel disease (Crohn’s disease and ulcerative colitis) is often 
associated with extra-intestinal manifestations, such as anterior uveitis or 
arthritis(5). The prevalence of axial disease in inflammatory bowel disease 
has been estimated at 5-12%(94). A higher prevalence has been noted in 
Crohn’s disease than in ulcerative colitis(95), and asymptomatic sacroiliitis 
has also been described(96). Conversely, axial spondyloarthritis is also 
accompanied by inflammatory bowel disease. In a recent meta-analysis, the 
pooled prevalence of inflammatory bowel disease in ankylosing spondylitis 
was 6.4% and in non-radiographic axial spondyloarthritis 4.1%(9). Nearly 
50% of patients with axial spondyloarthritis have also been shown to have a 
subclinical gut inflammation(97). 
2.4.3 Reactive arthritis  
Traditionally, reactive arthritis has been defined as “a sterile synovitis 
precipitated by an extra-articular infection”(98). No generally accepted 
classification criteria exist for the whole group of reactive arthritis(99, 100). 
At the fourth international workshop for reactive arthritis in 1999 it was, 
somewhat indistinctly, suggested that the term reactive arthritis should be 
used only for cases with symptoms typical for reactive arthritis, following an 
infection with microbes commonly associated with reactive arthritis(101).   
Since reactive arthritis often follows a self-limiting course, estimates of 
incidence in conjunction with different infections, are more common than 
estimates of prevalence.  Peaks in incidence have been repeatedly described 
in the aftermath of outbreaks of infectious enteritis, e.g. after an out-break of 
Salmonella in southern Sweden in 1974, 13 out of 330 enteritis-cases (4%) 
developed reactive arthritis(60), and similarly after an out-break of 
Campylobacter in Finland in 2000, 9 out of 350 enteritis-cases (2.6%) also 
developed reactive arthritis(102). After the water supply being contaminated 
with sewage in the town of Nokia in Finland 2007, only 21 cases (0.2%) of 
reactive arthritis were diagnosed, in the 8453 persons estimated to have 
caught gastroenteritis(103). More steady levels around 4-15% are reported in 
conjunction with symptomatic genital Chlamydia infections(99).  
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Axial disease in reactive arthritis is well described, but the estimates differ. 
HLA-B27 has been shown to predict a poorer prognosis, and the proportion 
of patients who develop a chronic axial phenotype, or progress to ankylosing 
spondylitis, likely depends on both HLA-B27 status and the infectious 
agent(101, 104).  
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3 ETIOLOGY 
 
Studies of familiar disease aggregation of ankylosing spondylitis in the 1950s 
showed that hereditary factors must play a major role in the disease 
etiology(78). The same, and subsequent, studies also indicated that not all 
individuals who inherit a genetic vulnerability for ankylosing spondylitis will 
develop the disease, and that heredity alone cannot predict disease 
phenotype(105). From this was hypothesized that the risk for an individual to 
acquire ankylosing spondylitis was likely conveyed through a combination of 
hereditary and exogenous factors, which will be discussed in the following 
sections.   
3.1 Genetic risk factors 
In 1973 the strong association between HLA-B27 and ankylosing spondylitis 
was described(106, 107). Since then, different models for the possible 
pathogenic effect of HLA-B27 have been suggested, but the evidence is still 
inconclusive. One proposed mechanism is the presentation of arthritogenic 
peptides. This is based on the theory that HLA-B27, during antigen 
presentation, can present microbial peptides similar to the individual’s own 
peptides (so called “molecular mimicry”), eliciting an auto-immune 
response(108). Other prosed mechanisms focus on the tendency of HLA-B27 
to fold incorrectly during synthesis and for the heavy chains to form dimers, 
which in turn may trigger inflammatory response through intra- and extra-
cellular pathways(108). Different types of HLA-B27, with only minor 
differences, are known to be more prevalent in different populations, and also 
have different degrees of association with ankylosing spondylitis, e.g. HLA-
B*27:05 is commonly associated with ankylosing spondylitis, but HLA-
B*27:06 is not(108, 109).  
Following the development of new genetic methods, in particular genome 
wide association studies, the understanding of the genetic base for ankylosing 
spondylitis has expanded rapidly. Now a number of different HLA-B alleles 
have been associated with ankylosing spondylitis, and a growing number of 
other genes as well, such as ERAP and IL23R(110, 111).  
Studies of the genetic overlap between ankylosing spondylitis and the related 
inflammatory disorders psoriasis and inflammatory bowel disease have also 
revealed a number of shared genes, among them IL23R and ERAP 1 and 
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2(2). IL23 is now considered to be central in the inflammatory pathway of 
ankylosing spondylitis and drugs targeting this have been developed both for 
ankylosing spondylitis and psoriatic arthritis, the IL-17 inhibitors(32, 112). 
Up to date, more than 40 genes have been associated with ankylosing 
spondylitis and the number is growing(2). 
3.2 Environmental risk factors 
A prevailing theory has been that either infections or traumatic exposures 
may trigger the development of ankylosing spondylitis(113, 114). The 
suspicion of traumatic risk factors was initially based on observations of 
trauma or prolonged mechanical stress, in the medical history of cases with 
ankylosing spondylitis, such as reports of long transports on trucks during the 
second world war and a high disease frequency among athletes(113). One 
suggested theoretical explanation, was that the axial predilection of the 
inflammation may be a result of a greater mechanical stress on the back and 
pelvis, compared to other locations(115).  
In the search for an infectious trigger for ankylosing spondylitis, urogenital 
infections were early seen as possible culprits(115). In one example from 
Sweden Romanus, in his thesis 1953, strongly favored a urogenital infectious 
etiology(116). This historical reasoning may partly be contributed to a lack of 
methods to differentiate between ankylosing spondylitis and reactive arthritis 
at that time, a problem which still exists.  
The support for a role for environmental triggers was further strengthened by 
studies of disease-concordance in mono- and dizygotic twins(105). While the 
twin-studies primarily supported the strong hereditary component of 
ankylosing spondylitis, the occurrence of discordant twins, in particular 
discordant monozygotic and HLA-B27 positive dizygotic twins, also 
implicated environmental exposures in the pathogenesis(117, 118). Later 
twin studies have confirmed this and have suggested that while genetic 
effects probably contribute to more than 90% of the risk, the remaining risk 
could be explained by environmental exposures(38, 119).  
3.2.1 Mechanical stress and non-infectious exposures 
In patients with an established diagnosis of ankylosing spondylitis, there are 
indications that non-infectious exogenous factors may affect the rate of 
radiographic progression. Two studies have shown that workers with “blue-
collar” occupations have a higher progression rate, compared to workers with 
“white-collar” occupations(40, 120). This would fit nicely with a hypothesis 
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suggesting that micro damage at entheses insertion, and the resulting 
inflammation, drives the new bone formation in spondyloarthritis(121). This 
has been supported by studies in a mouse model, based on mice with a 
chronic overproduction of TNF, that develop arthritis and gut inflammation, 
similar to spondyloarthritis(122). In this model, mice with unloaded hind legs 
(suspended by the tail) fail to develop arthritis in the ankle and hind 
paws(123). Furthermore, in a collagen-antibody-induced arthritis model, 
mice with unloaded hind legs developed significantly smaller osteophytes 
compared to controls(123). However, it is not known if the possible effect of 
mechanical stress on disease progression have any effect on onset of 
ankylosing spondylitis and other spondyloarthritis, or if it is only of 
importance in the established disease.  
A similar association between smoking, and a higher rate of radiographic 
progression, has also been shown(124), and one study has found that 
smoking may be a risk factor for incident ankylosing spondylitis (125), but 
this remains to be replicated. One case-control study has also suggested a 
protective effect associated with breastfeeding. This was theoretically 
attributed to the effect of breastfeeding on the development of the gut 
microbiota(126). 
Two studies have focused on birth order and the risk for developing 
ankylosing spondylitis. In the first, an increased risk was found for 
firstborns(127), but the second, much larger but otherwise similar, study did 
not confirm this(128). Birth order has been shown to be associated with the 
risk for a number of different immune-related disease, e.g. asthma and 
allergy(129). This is often attributed to the “hygiene hypothesis”, which 
suggests that having siblings may act as a proxy for an increased risk of 
exposure to infections at an early age, and that this may alter the immune-
phenotype. However, other explanations are also possible, such as different 
intrauterine conditions for firstborns compared to younger siblings.  
3.2.2 Infections 
Simultaneous to the description of the association between HLA-B27 and 
ankylosing spondylitis, a similar association was also shown for reactive 
arthritis(130), further strengthening the suspicions of an infectious origin for 
ankylosing spondylitis. A possible mechanism for such an association was 
provided when the possibility of antigen cross-reactivity between microbes 
and host was demonstrated (molecular mimicry discussed previously)(131). 
However, no such cross-reactivity mechanism has been conclusively proved 
in ankylosing spondylitis or the other spondyloarthritis diseases, and this 
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theory has been contradicted by studies indicating that HLA-B27 transgenic 
rats develop spontaneous spondyloarthritis, even when lacking CD8+ T-
cells(132). 
Intestinal flora and Klebsiella 
One attempt to link a specific infectious trigger to ankylosing spondylitis 
involved a study, published in 1977, analyzing the presence of Klebsiella and 
Yersinia in the feces and urine of patients with ankylosing spondylitis(133). 
The initial study, and subsequent studies, did demonstrate that Klebsiella was 
more common in feces of patients with active ankylosing spondylitis and that 
its presence predicted later development of active disease in patients with a 
low disease activity(134). Further studies also demonstrated elevated levels 
of antibodies, in particular IgA (suggesting a link to gut-mucosa), against 
Klebsiella in patients with ankylosing spondylitis(135, 136), a finding that 
has also been replicated in several independent cohorts(137-139).  
However, a more recent study comparing antibody pattern in axial 
spondyloarthritis, ankylosing spondylitis, blood donors and subjects with 
non-specific low back pain found no differences between the groups(140). 
Yet another study, comparing cellular and humoral immune response to 
Klebsiella, between members with and without ankylosing spondylitis, in 
families with ankylosing spondylitis, also found no differences(141).  
More contemporary studies of gut flora, have not been able to replicate the 
previous findings of Klebsiella in the feces of subjects with ankylosing 
spondylitis, or that it would correlate to disease activity(142, 143). What has 
been found, using 16s-RNA sequencing, is that patients with ankylosing 
spondylitis have a different microbial composition in the gut, compared to 
healthy controls, and that this composition at least partly corresponds to 
species known to be associated with inflammatory bowel disease(144-146). It 
has also been shown that patients with ankylosing spondylitis, and their first-
degree relatives, may have an increased gut-permeability in the small 
intestine(3), providing a potential locus for exposure to microbial antigens. 
In a transgenic rat-model of ankylosing spondylitis, expressing HLA-B27, 
the animals spontaneously develop a disease similar too human 
spondyloarthritis, including gut inflammation. If reared under germ-free 
conditions, the rats fail to develop both arthritis and gut-inflammation, 
strongly suggesting a pathogenic role of microbes in this particular animal 
model(147). Similar results have also been presented for a mouse 
model(148). However, is has also been shown that HLA-B27 transgenic rats 
have a different gut microbiota, compared to co-reared wild type rats, 
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indicating that the host genotype may also influence the microbial 
composition in the gut(149).  
The hypothetical role of Klebsiella in the development of ankylosing 
spondylitis is still debated, and there are strong opinions offered both in favor 
of it(150) and against it (151). It could be that Klebsiella is rather a marker of 
gut lesions, than involved in the pathogenesis, but considering the sheer 
amount of data published on the topic a systematic review, by an independent 
researcher, may be appropriate to sort out the results. Further, the link 
between the microbial flora of the gut, intestinal inflammation, and 
spondyloarthritis is a current focus for research. 
3.3 Comparisons with related diseases 
Considering the genetic overlap (described previously), between the 
inflammatory disorders related to spondyloarthritis, it is possible that they 
also share environmental risk factors, which may justify a comparison as 
follows. 
3.3.1 Inflammatory bowel disease 
In inflammatory bowel disease, there are more epidemiological data 
supporting a role for environmental factors in the pathogenesis, compared to 
ankylosing spondylitis. For both ulcerative colitis and Crohn’s disease it is 
accepted that bacterial enteritis may trigger disease onset, and both animal 
and human data indicates that gut flora is important both in the pathogenesis 
and for the severity of the conditions (5, 152). In ulcerative colitis a 
protective association has also repeatedly been described for smoking and 
breastfeeding(152), while in Crohn’s disease smoking appears to increase the 
risk(5).  
Elevated serological markers for Klebsiella have also been previously 
described in inflammatory bowel disease(153), but at least one study has 
failed to detect Klebsiella in tissue cultures from inflammatory bowel 
disease(154). 
Appendectomy and appendicitis have been linked to a decreased risk of 
subsequent development of ulcerative colitis(155, 156). For Crohn’s disease, 
the results have been more divergent, and a recent meta-analysis found the 
over-all effect to be an increase in risk(157). Much of this increase in risk 
was, however, related to an increase in incidence of Crohn’s disease in the 
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year following the appendectomy, wherefore it can be suspected that it was 
instead incipient Crohn’s disease. 
At least ten epidemiological studies have investigated the association 
between inflammatory bowel disease and season, or month, of birth. The 
results are not consistent, in that some point to increases in risk depending on 
season or month(158), or a cyclic pattern(159), but others find no 
association(160). Different mechanisms have been suggested for the 
associations seen between season of birth and risk for later disease 
development in some diseases, such as seasonal variations in infectious 
exposure, or seasonal variations in Vitamin-D levels. 
3.3.2 Psoriasis 
Infections with streptococci, usually throat infections, can trigger the acute 
guttate form of psoriasis(161), and some data indicate that it can also be 
associated with exacerbations in the chronic plaque disease(162). Cutaneous 
psoriasis can also manifest as a Koebner phenomenon, affecting previously 
scarred or traumatized skin(163). There some are data suggesting that both 
infections and trauma, including mechanical stress, may be associated with 
the development of psoriatic arthritis in subjects with cutaneous 
psoriasis(164-166), but the exact role, or mechanism, of this has not been 
determined. 
3.3.3 Reactive arthritis 
The typical infections associated with reactive arthritis (and originally with 
Reiters syndrome) are bacteria causing enteritis (Salmonella, Shigella, 
Campylobacter and Yersinia) or urogenital infections (Chlamydia), but many 
other bacteria have also been reported to trigger it(101). The mechanisms, by 
which the infections trigger reactive arthritis, are not conclusively 
determined.  
There are reasons to suspect that the mechanisms involved in the 
pathogenesis may differ between different pathogens. Specifically, research 
on Chlamydia-induced reactive arthritis has challenged the concept of an 
aseptic arthritis, as both DNA and RNA of Chlamydia can be detected in the 
synovial tissues, including examples of detection in the sacroiliac joints(167). 
In addition, DNA from Yersinia enterocolitica has also been detected in 
synovial fluid in reactive arthritis(168) and there is also some support for an 
effect of antibiotics in chlamydia induced arthritis(169). However, detection 
of Chlamydia in joints, with PCR, have also been reported for other types of 
arthritis, as well as from osteoarthritis, so its role is unclear(170).  
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4 SUMMARY OF METHODS 
4.1 Objectives 
To validate the diagnoses of ankylosing spondylitis and undifferentiated 
spondyloarthritis in the Swedish national patient register, and to investigate 
the possible identification of incident cases in the register (study I). 
To estimate the prevalence of ankylosing spondylitis in Sweden, and to 
stratify the prevalence according to age, sex, geographical and socioeconomic 
factors, and in relation to clinical manifestation and pharmacological 
treatment. And to compare pharmacological treatment and disease 
manifestations between men and women (study II). 
 To assess, and compare the frequency of current inflammatory back pain in 
ankylosing spondylitis, psoriatic arthritis and “other spondyloarthritis”, and 
to compare self-reported disease activity between the subsets with current 
inflammatory back pain (study III). 
To investigate predictive associations between perinatal characteristics, (in 
particular birth order, birth weight and season of birth), as well as childhood 
infections (in particular enteric and urogenital infection), with later 
development of ankylosing spondylitis (study IV and V).   
4.2 Data sources 
The studies in this thesis are based on subjects identified through two 
different register. In study I, II, IV and V the subjects were identified through 
the Swedish national patient register, and study III through the Skåne Health 
Care Register. Apart from these sources, data were also cross-linked from 
five other national registers, and in study III from a postal survey. The 
registers and the survey are described in the following section. 
National patient register 
The national patient register started in 1964 as a hospitalization register, 
recording medical, demographic and administrative data on patients 
discharged from inpatient care. The coverage of the register increased 
gradually and is considered to be almost 100% (covering both private and 
public hospitals) since 1987. In 2001 a register for specialized outpatient care 
was added to the patient register, this has a lower coverage, around 80%, 
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primarily due to missing data from private care. There is no register on a 
national level including primary care. Diagnoses are registered according to 
International Classification of Diseases (ICD) codes. 
Prescribed drugs register 
The register was started in July 2005 and collects data on all prescribed 
drugs, at the time they are dispensed from a pharmacy, in Sweden. It does not 
cover over-the-counter drugs or drugs that are prescribed but not collected by 
the patient. 
Swedish Rheumatology Quality Register 
A treatment and follow-up register for rheumatic diseases that was initiated in 
the 1990s. It includes patients with rheumatoid arthritis, spondyloarthritis and 
a growing number of systemic rheumatic diseases. The coverage for patients 
treated with biologics was recently estimated to be around 95% for 
rheumatoid arthritis and 86% for spondyloarthritis.  
Population register 
This register is managed by the Swedish administrative authority, Statistics 
Sweden, and collects demographic data on people living in Sweden, such as 
migration, level of education and income.  
Medical Birth Register 
Initiated in 1973, the medical birth register collects medical, administrative, 
and some demographic data concerning prenatal care, delivery and postnatal 
care.  
Skåne Health Care register 
The Skåne Health Care register is a regional register in the region of Skåne 
(southern part of Sweden). It contains much of the same medical and 
administrative data as the national patient register, of which it is also a part, 
but it also covers public and private primary care in the region.  
Cause-of-Death register 
A national register that collects data on date of death and cause of death in 
Sweden. 
SpAScania Questionnaire  
The questionnaire, sent to patients with spondyloarthritis diagnoses, in study 
III was composed by a group of two specialists in rheumatology, one general 
practitioner, one health economist and two physiotherapists. It included 
questions related to health and disease, lifestyle, exercise, demographics, 
Ulf Lindström 
23 
treatment, health economics and a number of disease outcome measures. 
Examples of outcome measures included in the questionnaire were the Bath 
ankylosing spondylitis disease activity and functional indices (BASDAI and 
BASIF), the health assessment questionnaire (HAQ), and the European 
quality of life-5 dimensions index (EQ-5D). The questionnaire was tested in, 
and adjusted according to, three small focus groups with patients with 
spondyloarthritis and one patient research partner, before being sent to the 
study group in 2009. Two reminders were sent to the subject who did not 
respond.  
4.3 Study design and statistical analysis 
 
4.3.1 Study I  
The primary objective was to identify patients with ankylosing spondylitis 
and undifferentiated spondyloarthritis, in the national patient register, and to 
determine the validity of these diagnoses. The secondary objective was to 
determine if incident cases of ankylosing spondylitis or undifferentiated 
spondyloarthritis could be identified through the register.   
All patients receiving a registered diagnosis of ankylosing spondylitis and 
undifferentiated spondyloarthritis in the patient register 1966-2009, still 
living and residing in Sweden in 2009, were identified. 1966 was set as the 
start of the period, since the first version of the New York criteria was 
proposed then(171). 
In order to determine the validity of the diagnoses, the medical records of a 
sample of patients identified through the register were examined. The sample 
was selected randomly, but on the premises that the patients had been given 
the diagnosis at least once in 2007-2009, in one of five rheumatology clinics 
(100 at each, a total of 500 patients) in Sweden. Half of the cases were 
selected as possible prevalent cases, also having a registered diagnosis prior 
to 2007, and half as possible incident cases, with no registered diagnosis prior 
to 2007. The five clinics were selected to represent the different geographical 
regions in Sweden, as well as to include larger and smaller clinics.  
The medical records were examined according to a pre-specified Case Report 
Form (CRF), extracting the data needed to determine if the patients fulfilled 
the following classification criteria for spondyloarthritis: the modified New 
York criteria(13), the ESSG criteria(14), the Amor criteria(15) and the ASAS 
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criteria for both axial(12) and peripheral(16) spondyloarthritis. Information 
was also sought for weather the treating physician was certain that they had 
the diagnosis or not – the “expert opinion”. 
The secondary objective was to determine if incident cases could be 
identified in the register. In order to determine if the patients in the sample 
population, without a registered diagnosis prior to 2007, were incident cases, 
data was collected from the medical records concerning the time-point of 
symptom onset. 
For the purpose of assessing the generalizability of the results from the 
validation exercise, comparisons were made to all cases registered in the 
patient register, with the respective diagnoses, in terms of the frequencies of 
the related inflammatory disorders; anterior uveitis, inflammatory bowel 
disease and psoriasis. A comparison was also made to a subset of the register 
population, who had been given the respective diagnosis at least once at a 
clinic of rheumatology or internal medicine. 
Statistical methods 
Positive predictive values (PPV) for fulfilling the different criteria sets, being 
given a diagnosis of ankylosing spondylitis or undifferentiated spondylo-
arthritis in the register, were calculated. Subset analyses were performed for 
the portion of cases where information on imaging results and HLA-B27 
status were available.  
Chi2 test were used to compare the frequencies of fulfilling the different 
criteria sets between the five different hospitals and stratified on sex and age 
(above/below median). 
4.3.2 Study II – cross sectional study 
The primary objective was to determine the point prevalence of ankylosing 
spondylitis in Sweden on the 31 of December 2009, and to stratify this on 
age, sex, pharmacological treatment, disease manifestations, and geo-
graphical and socioeconomic factors. The secondary objective was to 
compare disease manifestations and treatment between men and women 
All individuals, aged 16-64 years in 2009, given a diagnosis of ankylosing 
spondylitis in the patient register 1967-2009 were identified. Two case 
definitions of ankylosing spondylitis were analyzed, a (i) “base case” and a 
(ii) “strict case”, corresponding to (i) the whole population in the register, and 
(ii) the subset with at least one diagnosis from a clinic of rheumatology or 
internal medicine (the same categories described in study I). Data were cross-
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linked from the prescribed drugs register, the Rheumatology Quality 
Register, the population register and the cause-of-death register.  
Comparisons of prevalence stratified on socioeconomic status were based on 
the individual patients’ highest recorded level of formal education. In this 
comparison, only patients 30 years or older were included, since by then the 
majority were assumed to have finished their formal education. 
Statistical methods 
The point-prevalence was calculated based on the cumulative incidence of 
registered codes for ankylosing spondylitis up until 31 December 2009. 
Subgroup prevalence was determined for men/women, age-groups, disease 
manifestations and pharmacological treatment. Age- and sex-standardized 
prevalence was calculated for the different health care regions in Sweden and 
for the different levels of formal education, standardizing to the Swedish 
population in 2009.  
For statistical comparisons, non-overlap of 95% confidence intervals were 
used in the comparison of geographic distribution and level of education. 
Chi2-tests and t-tests were used to compare the demographics, treatment and 
disease manifestations between men and women. In order to further analyze 
the difference in treatment, between men and women, a logistic regression 
model was used to adjust for potential confounders (age and disease 
manifestations). 
4.3.3 Study III – cross sectional study. 
The objectives were to describe and compare the frequency of current 
inflammatory back pain, between patients with a diagnosis of ankylosing 
spondylitis, psoriatic arthritis and other spondyloarthritis, and to compare the 
self-perceived health status in the subsets with current inflammatory back 
pain. The rationale behind this comparison was the assumption that 
symptoms of inflammatory back pain may be used as a marker for an axial 
disease in cases diagnosed with spondyloarthritis.  
The patients were identified through the Skåne Health Care Register, based 
on having been given a diagnosis of any type of spondyloarthritis, in 2003-
2007, and aged 15 years or older. In 2009 all subjects, then aged 18 years or 
older and still residing in the county, were sent a postal survey (the 
SpAScania questionnaire described previously). Data were also collected 
from the prescribed drugs register and the Rheumatology Quality Register, 
for anti-rheumatic treatment.  
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Among the responders to the survey, all subjects reporting symptoms 
compatible with current inflammatory back pain were identified, based on 
reporting more than three months of low back pain during the last 12 months, 
and fulfilling the Berlin criteria(22) for inflammatory back pain. The 
proportion of subjects with current inflammatory back pain were compared 
between the three groups. Comparisons of patient reported outcome 
measures, treatment, demographics and related inflammatory disorders, were 
then performed between the groups reporting current inflammatory back 
pain. 
Statistical methods 
Comparisons between the different subgroups of spondyloarthritis, and 
between responders and non-responders, were done using Fisher’s exact test 
and independent sample t-tests, also applying a Bonferroni correction due to 
multiple testing. Concordance between register data and survey data was 
determined through Cohen’s kappa. 
4.3.4 Study IV – case-control study 
The objective was to investigate possible associations between perinatal 
characteristic, in particular birth weight, birth order and season of birth, and 
later development of ankylosing spondylitis.  
Cases with ankylosing spondylitis were identified through the national 
patient register, but limited to those borne in Sweden in 1973 or later (when 
the medical birth register started). A control population was retrieved from 
the population register, matched on sex, birth year and county of birth at the 
time-point of the index cases´ first registered spondyloarthritis diagnosis (the 
closest approximation to the time-point of disease onset available in the 
register).  Data were then retrieved from the medical birth register, for 
perinatal characteristics, and linked to data from the prescribed drugs register, 
the Rheumatology Quality Register and the national patient register.  
The cases and controls were compared in terms of the frequencies of the 
specific perinatal features and both simple and adjusted odds ratios were 
computed for each characteristic.  
Statistical methods 
Comparisons between the cases and controls, with regard to level of formal 
education (2008), maternal diabetes and disposable income (2008) were 
performed using Chi2-test, Fisher’s exact test and t-tests. Odds ratios were 
determined though simple conditional logistic regression and a multiple 
conditional logistic regression model also adjusting for possible confounders 
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(gestational length, maternal age, type of birth). Two measures of 
socioeconomic status (the mother’s civil status and country of birth) and the 
size of the delivery unit were also included in the model.  
The multiple logistic regression model was also applied in four sensitivity 
analyses. First, excluding cases and controls with a registered diagnosis of 
psoriasis, inflammatory bowel disease or anterior uveitis up until two years 
after the first registered diagnosis of ankylosing spondylitis. Second, only 
including cases with anti-rheumatic treatment during 2011. Third, including 
only cases who had received a diagnosis of ankylosing spondylitis at least 
once at a clinic of rheumatology or internal medicine (in analogy with the 
definitions used on study I and II). Fourth, only including cases receiving the 
diagnosis at least once in outpatient specialized care in 2001-2009.  
4.3.5 Study V – case-control study 
The objective was to investigate associations between childhood infections 
and later development of ankylosing spondylitis. It was specifically 
hypothesized that there may be an association with enteric and urogenital 
infections, considering the similarities with reactive arthritis and the possible 
role of gut inflammation in ankylosing spondylitis. 
Cases were identified based on a diagnosis of ankylosing spondylitis in the 
specialized care outpatient register 2001-2010. Controls were retrieved from 
the population register, matched on sex, birth year and county of birth, at the 
time-point of the index cases’ first registered diagnosis of spondyloarthritis. 
Both cases and controls had to be born in Sweden in 1964 or later (start of the 
patient register) and to have lived in Sweden at least up to their 17th birthday 
(exposure period 0-16 years).  
Data on pharmacological treatment were obtained from the prescribed drugs 
register and the Rheumatology Quality Register, and data on other rheumatic 
diseases and related inflammatory disorders from the patient register. All 
cases and controls matched before the age of 17, or receiving any other 
rheumatic diagnosis or related inflammatory diagnosis before match were 
excluded, as well as all receiving a diagnosis of reactive arthritis or juvenile 
arthritis at any time-point.  
Occasions of hospitalization with an infection before the age of 17 were 
extracted from the patient register, and compared between the cases and 
controls based on frequencies and through determining odds ratios. The 
infectious diagnoses were analyzed as a whole as well as categorized 
according to their primary focus. 
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Statistical methods 
Odds ratios were determined though simple conditional logistic regression. 
Two sensitivity analyses were performed as a result of the risk for reverse 
causality. First, only including cases and controls matched at an age of 27 
years or older, giving a minimum of 10 years between exposures and match. 
Second, only including those matched in 2007-2010, making it possible to 
also exclude anyone treated with immunosuppressive or cytostatic drug in the 
year prior to match. In the latter analysis, the use of antibiotics during the 
year prior to match, was also compared between the cases and controls using 
Fisher’s exact test.  
A third sensitivity analysis included only cases with anti-rheumatic treatment, 
likely to represent a more severe/active phenotype. One post hoc sensitivity 
analysis was also performed, excluding all cases and controls with a 
diagnosis of inflammatory bowel disease. Three additional, stratified, 
analyses were also included, stratifying on median age at match, and median 
age at appendectomy and tonsillectomy. 
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5 SUMMARY OF RESULTS 
 
5.1 Study I  
 15120 patients with ankylosing spondylitis and 14553 with undifferentiated 
spondyloarthritis (and never a diagnosis of ankylosing spondylitis), living in 
Sweden in 2009, were identified through the national patient register. Of the 
patients with ankylosing spondylitis, 76% had at least one registered 
diagnosis at a clinic of rheumatology or internal medicine, for undifferen-
tiated spondyloarthritis this was 59%. 
For the sample population of 500 patients, selected for the validation 
exercise, the medical records were located for 499. For 220, of the 250 
patients identified as ankylosing spondylitis, the radiographic data needed to 
apply the modified New York criteria were found. Based on these 220 
patients, the PPV for fulfilling the modified New York criteria was 80% 
(table 6).  
For 166 of the 186 patients, identified as undifferentiated spondyloarthritis, 
and never having been given a registered diagnosis of ankylosing spondylitis, 
either imaging or HLA-B27 status was found, making it possible to assess the 
different spondyloarthritis criteria. Of these 166, 89% fulfilled at least one of 
the criteria for spondyloarthritis and 82% either of the ASAS-criteria. Only 
26% of the patients identified as undifferentiated spondyloarthritis, with 
available radiographic data on the sacroiliac joints, fulfilled the modified 
New York criteria, as seen in table 6. Patients with registered diagnoses of 
both ankylosing spondylitis and undifferentiated spondyloarthritis were over-
all more similar to the ankylosing spondylitis group. 
Part of the validation was also intended to depend on the “expert opinion” of 
the physician, concerning the diagnosis, since this is often considered the 
golden standard. This was not possible to determine, due to the difficulty to 
extract this information from the medical records in a structured manner.  
For the secondary objective of identifying incident cases the hypothesis was 
that if a patient had not received a diagnosis in either the inpatient register 
1966-2006, or in the outpatient specialized care register 2001-2006, they 
could be an incident case. This however, proved to be false as the mean time 
from symptom debut (according to the medical records) and the first 
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diagnosis (in the register), for this subgroup was 16.6 years for ankylosing 
spondylitis and 9.2 years for undifferentiated spondyloarthritis. 
 The frequency of criteria fulfillment in the validated sample. 
 
The generalizability of the PPVs were assessed through a comparison of the 
frequencies of psoriasis, inflammatory bowel disease and anterior uveitis in 
the validated sample, with different register subsets, as presented in table 7. 
The conclusion was that the frequencies were similar in the validated sample, 
compared to both the whole population in the register (AS-1/uSpA-1), and 
the subset with a diagnosis from a clinic of rheumatology or internal 
medicine (AS-2/uSpA-2), supporting the generalizability.  
 
 
 
Criteria fulfillment AS uSpA 
without AS 
Overlap AS 
and uSpA 
All validated cases (n=250) (n=186) (n=137) 
New York (modified) 176 (70) 37 (20) 96 (70) 
ASAS-axial 197 (79) 82 (44) 111 (81) 
ASAS-peripheral 122 (49) 106 (57) 85 (62) 
ASAS-axial/peripheral 215 (86) 136 (73) 125 (91) 
ESSG 200 (80) 111 (60) 119 (87) 
Amor 207 (83) 120 (65) 127 (93) 
Any of the SpA-criteria 222 (89) 147 (79) 131 (96) 
Available data on radiographic sacroiliitis (n=220) (n=143) (n=124) 
New York (modified)  176 (80) 37 (26) 96 (77) 
Available data on imaging and/or HLA-B27  (n=230) (n=166) (n=131) 
ASAS-axial  197 (86) 82 (49) 111 (85) 
ASAS-axial/peripheral  215 (93) 136 (82) 125 (95) 
Amor 207 (90) 120 (72) 127 (97) 
Any of the SpA-criteria 222 (97) 147 (89) 131 (100) 
Data are based on review of 500 medical records. Results are given separately for patients 
with a diagnosis of ankylosing spondylitis (AS), undifferentiated spondyloarthritis (uSpA, 
without AS) and the overlapping cases (73 of which are also included in the AS group). 
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 The frequency of anterior uveitis, psoriasis and inflammatory bowel 
disease (IBD) in the cohorts of ankylosing spondylitis (AS) and 
undifferentiated spondyloarthritis (uSpA) (without AS) in the national patient 
register, 1966-2009, and in the validated sample.  
 
5.2 Study II 
The point prevalence of ankylosing spondylitis in Sweden 31 December 
2009, in the age-group 16-64 years, was calculated to be 0.14% with the strict 
case definition and 0.18% with the base case definition, and 64% were men.  
There were differences between men and women both regarding disease 
manifestations and treatment, with a higher proportion of men having a 
registered diagnosis of anterior uveitis and more women having psoriasis and 
peripheral arthritis. Men also received treatment with TNF-inhibitors more 
frequently, and women treatment with glucocorticoid steroids. When the 
treatment differences were analyzed in the logistic regression model, 
adjusting for disease manifestations and age, the same pattern was observed.  
Ankylosing spondylitis  Undifferentiated spondyloarthritis  
 AS-1 AS-2 Validated uSpA-1 uSpA-2 Validated  
Total number 15120 11472 250 14553 8617 186 
Women  
(%) 
5325  
(35) 
3899 
(34) 
86  
(34) 
8865  
(61) 
5062  
(59) 
103  
(55) 
Uveitis  
(%) 
3229  
(21) 
2601 
(23) 
86 
(34) 
1166  
(8) 
1146  
(13) 
44  
(24) 
Psoriasis  
(%) 
1094  
(7) 
899  
(8) 
15  
(6) 
1095  
(8) 
901  
(11) 
15  
(8) 
IBD  
(%) 
1202  
(8) 
995  
(9) 
10  
(4) 
643  
(4) 
517  
(6) 
9  
(5) 
AS-1: ≥1diagnosis of AS in the whole patient register. 
AS-2: ≥ 1 diagnosis of AS at department of rheumatology or internal medicine 
uSpA-1:  ≥1diagnosis of uSpA, and never an AS-diagnosis, in the whole patient register 
uSpA-2: ≥1 diagnosis of uSpA at department of rheumatology or internal medicine, and 
never an AS-diagnosis 
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The crude and standardized prevalence, stratified on health care regions, are 
presented in figure 1. The prevalence was higher in northern Sweden 
compared to the southern parts. Prevalence in relation to socioeconomic 
status, based on the highest recorded level of formal education, is presented 
in figure 2. There was a lower prevalence of ankylosing spondylitis in the 
group with more than 12 years of formal education, compared to the other 
groups. This difference remained after stratifying on age, but was more 
pronounced in the older age-groups.  
Figure 1. The point-prevalence of ankylosing spondylitis in Sweden, 31 December 
2009, in the different health care regions in Sweden, presented as crude 
prevalence and standardized according to age and sex, to the Swedish population. 
In the figure corresponding to figure 1 in the published study there was a 
computational error concerning the standardized rates, which is corrected in this 
version. 
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Figure 2.  The point-prevalence of ankylosing spondylitis in Sweden, 31 
December 2009, stratified on length of formal education, presented as crude 
prevalence and standardized according to age and sex, to the Swedish 
population. In the figure corresponding to figure 2 in the published study 
there was a computational error concerning the standardized rates, which is 
corrected in this version. 
5.3 Study III 
5771 patients were identified in the Skåne Health Care Register, given a 
spondyloarthritis diagnosis in 2003-2007, and being 18 years or older and 
still living in the county in 2009, of which 2785 (48%) responded to the 
survey. 1010 (36% of responders) reported more than three months of low 
back pain during the last 12 months and fulfilled the Berlin criteria for 
inflammatory back pain at the time of the survey, based on self-reported 
symptoms. Within the responder group the proportion of subjects reporting 
current inflammatory back pain, was higher, but similar, for ankylosing 
spondylitis (43%), compared to the other two groups (31% for psoriatic 
arthritis and 39% for “other spondyloarthritis”).  
The three groups, reporting current inflammatory back pain, had similar 
levels of self-perceived health status, but with a consistent trend for worse 
reporting from the groups other than ankylosing spondylitis, and a higher 
proportion of pharmacological treatment in the group with psoriatic arthritis, 
as presented in table 8. The kappa-values and proportion of agreement, 
between the survey and register data, were very good indicating a high 
concordance between the different sources. 
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 Comparisons of demographics, frequency of related inflammatory 
disorders, patient reported outcome measures and pharmacological 
treatment, between clinically diagnosed ankylosing spondylitis, psoriatic 
arthritis and” other spondyloarthritis”, all reporting current inflammatory 
back pain. 
 
 
 AS with current 
IBP  
n=319 
PsA with 
current IBP 
n=409 
Other-SpA with 
current IBP 
n=282 
Demographics    
Age 2009, mean (sd)  54 (13) 57 (13) 53 (15) 
Sex, n men (%)  182 (57) 129 (32)2 87 (31)2 
SpA-related disease, n (%)    
Uveitis  63 (20) 9 (2)2 37 (13) 2, 4 
Psoriasis 19 (6) 407 (100)2 0 
Inflammatory bowel disease 25 (8) 21 (5) 36 (13)4 
PROMS, mean (95% Cl)    
NRS-spinal pain 5.9 (5.6-6.1) 6.1 (5.9-6.4) 6.2 (6.0-6.5)1 
NRS-fatigue  5.8 (5.6-6.1) 6.2 (5.9-6.4)1 6.1 (5.8-6.4) 
NRS-patients global 5.2 (4.9-5.4) 5.4 (5.2-5.6) 5.5 (5.2-5.7) 
BASDAI  5.1 (4.8-5.3) 5.7 (5.5-5.8)2 5.5 (5.3-5.8)1 
BASFI  4.4 (4.2-4.7) 4.8 (4.5-5.0) 4.4 (4.1-4.7) 
EQ-5D 0.68 (0.66-0.70) 0.65 (0.63-0.67) 0.67 (0.64-0.69) 
Treatment, n (%)    
Etanercept  27 (9) 54 (13)1 15 (5)4 
Adalimumab 12 (4) 32 (8)1 9 (3)3 
Methotrexate  37 (12) 151 (37)2 33 (12)4 
Sulphasalazine  28 (9) 14 (3)1 24 (9)3 
AS=ankylosing spondylitis, IBD= inflammatory bowel disease; NRS= Numerical Rating 
Scale 1–10; BASDAI= Bath Ankylosing Spondylitis Activity Index; BASFI= Bath 
Ankylosing Spondylitis Functional Index, PROMs = Patient-reported outcome measures, 
IBP= inflammatory back pain. 
1) p<0.05 compared with AS; 2) p<0.00125 (Bonferroni correction) compared with AS; 
3) p<0.05 compared with PsA; 4) p<0.00125 compared with PsA (Bonferroni correction) 
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5.4 Study IV 
Based on 1960 cases with ankylosing spondylitis and 8377 matched controls, 
the proportion of cases with older siblings was slightly higher than that of the 
controls (62% vs. 58%), with an odds ratio of 1.18 (1.06 to 1.30) based on the 
simple conditional logistic regression analysis. For the other two perinatal 
characteristics primarily assessed (birth weight and season of birth), as well 
as the other features included in the comparison (see study IV for details), 
there were no differences between the cases and the controls. However, birth 
weight was found to be sensitive to how the cut-offs for categorization were 
chosen, so that while using the WHO definitions for birth weight (<2500g, 
2500g-4200g, >4200g) no differences were detected. But when using more 
evenly balanced categorizations, either based on tertiles or on categories used 
in previous studies, there appeared to be a signal for an increased risk of 
ankylosing spondylitis associated with low birth weight. 
Birth order and birth weight were included in the multiple logistic regression 
model, as well as the confounding factors, socioeconomic measures and size 
of delivery unit, as described in the methods section. Season of birth was not 
entered in the model, since it did not differ between cases and controls, with 
regard to proportions or simple odds ratios. The odds ratios for birth order 
and birth weight, computed through the model, are presented in figure 3. 
Overall the sensitivity analyses resulted in endpoints with similar magnitude 
and direction. 
Figure 3. Forest plot presenting the odds ratios (OR) and 95% confidence intervals 
(CI) for being diagnosed with ankylosing spondylitis, with regard to birth order and 
birth weight, in the multiple conditional logistic regression model. 
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5.5 Study V 
2453 cases, with ankylosing spondylitis, and 10257 matched controls, 
fulfilled the study criteria. For the two types of infections, enteric and 
urogenital, where there were hypothesized to be an association with later 
development of ankylosing spondylitis, no such relationship was detected. 
Instead, there was an increased risk associated with respiratory tract 
infections, and in particular with tonsillitis. There was also a negative 
association with appendicitis and appendectomy, see figure 4.   
Figure 4.  Forest plot presenting the odds ratios (OR) and 95% confidence intervals 
(CI) for being diagnosed with ankylosing spondylitis, with regard to hospitalization 
with different types of infections during childhood. 
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The direction and magnitude of the point estimates were similar in the 
sensitivity analyses, and in the second sensitivity analysis there was no 
statistical difference between the cases and controls with regard to 
prescriptions of antibiotics in the year prior to match. The stratified analyses 
suggested a stronger association with appendectomy if performed at a young 
age, and a stronger association with tonsillitis/tonsillectomy for the group 
receiving their first spondyloarthritis diagnosis at a younger age. 
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6 DISCUSSION 
6.1 Methodology – study design 
The quality of a study relies on the choice of an appropriate study design, 
how it is conducted, and the internal and external validity.  Internal validity 
refers to how accurate the results of the study are, within the studied sample 
population. The internal validity can be reduced by faults in study design, 
systematic errors (bias) and confounding. External validity refers to how well 
the results of the study can be generalized to other populations. The external 
validity can be reduced by limitations in the internal validity, but is also 
dependent of the specific situation of the generalization. In this section the 
strengths and limitations of the different study designs, used in this thesis, 
will be discussed.  
Study I 
The main objective of study I was to determine the validity of the diagnoses 
in the register population. For this purpose, a sample of the population was 
chosen, on premises that were partly set up in order to maximize the 
probability of retrieving the relevant medical records. This was in fact a 
trade-off, between finding the relevant data and validating a representative 
sample. This limitation in the study design introduced a selection bias, which 
needed to be addressed. 
The problem of selection bias in study I was dealt with by comparing the 
frequencies of the related inflammatory disorders, within different subsets of 
the register population (table 7), and it was concluded that the validated 
sample was similar enough to the register populations to extrapolate the 
results. The frequencies of anterior uveitis, psoriasis and inflammatory bowel 
disease in the whole register cohort, were also very similar to the frequencies 
of extra-articular manifestations presented in a meta-analysis 2014 (25.8%, 
9.3% and 6.8%, respectively)(172), further supporting the validity.  
Retrieving data from medical records spanning several decades is 
cumbersome and information will be missed or lost, frequently in a biased 
way. For example, single episodes of dactylitis or enthesitis are more likely 
not to be recorded, or not found in the review, compared to radiographic 
findings. It is therefore probable that PPVs calculated in study I rather 
underestimates the validity of the diagnoses in the register, since a criterion 
not found was treated as a negative finding.  
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Study II and III 
Study II and III were designed as cross-sectional analyses, which can be a 
suitable design when studying disease occurrence and comparing different 
groups. One drawback is that there is no temporal aspect in the study design 
and therefore also very little opportunity for any causal inference. In study II 
this limits the conclusions that can be reached, for possible reasons for a 
difference in prevalence, depending on length of education. It cannot be 
differentiated, in a cross-sectional study, whether having ankylosing 
spondylitis may lead to a lower level of education, for example due to an 
impact on daily function, or whether having a shorter education is a risk 
factor for developing ankylosing spondylitis.  
In study I the validity of the diagnostic codes were determined based on 
PPVs. In a prevalence study, such as study II, the accuracy of the prevalence 
estimates would depend more on the sensitivity and specificity of the method 
for case-identification (in this case ICD-codes), than on PPVs. If the 
specificity of the diagnostic codes, for ankylosing spondylitis, is low in the 
register, the prevalence would be overestimated in study II. And if the 
sensitivity is low it would instead lead to an underestimation. The sensitivity 
and specificity cannot be determined for the diagnostic codes in the register, 
since there are no data on the “true negative” and “false negative” cases in 
the Swedish population.  
Study IV and V 
Study IV and V were conducted as case-control studies, which is often an 
efficient design for studying the effect of exposures when the outcome is 
relatively rare. Due to the study design, there was a risk for reverse causality 
in study V, since the time point of disease onset cannot be precisely 
determined through the registers. To increase the probability of the exposures 
occurring before the outcome, several sensitivity analyses were performed, 
excluding cases and controls with any suspicion of a pre-existing 
inflammatory disorder prior to matching, which resulted in no substantial 
changes in the point estimates. In study IV a number of possible confounders 
were also included in the regression model, but residual confounding may 
still affect the results. 
6.1.1 Systematic errors - bias  
When designing, and interpreting the results of an epidemiological study two 
main categories of bias must be considered: selection bias, referring to any 
bias resulting from the selection procedure, and information bias, referring to 
any bias introduced in the data for exposures or outcomes. Selection bias can, 
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for instance, result in a study sample that is not representative, hence 
decreasing the external validity, while information bias may affect both the 
internal and external validity. To determine how much the bias threatens the 
validity of the study, the magnitude and direction of it should be estimated.  
In all register based studies there are also to some extent a problem with 
misclassification. Misclassification can result in a bias if, for example in a 
case-control study, classification of exposures is different between cases and 
controls. Misclassification resulting in a bias is often referred to as directional 
misclassification, in contrast to non-directional misclassification where the 
effect is the same in the different studied groups. Non-directional 
misclassification can still result in underestimations of the associations 
searched for.  
Potential problems with the study design and validity in study I, where the 
possibility of selection bias is closely related to the objectives and design of 
the study, have been discussed in the previous section, the possible impact of 
bias in the other studies is discussed below. 
Study II 
In study II there is a risk of selection bias influencing the prevalence 
estimates. Selecting cases based on codes in the national patient register, only 
detects individuals who have sought help from the health care system, or who 
are not exclusively treated in primary care, which may result in an 
underestimation of the true prevalence in the population (the population in 
this context being the population of Sweden).  
Few studies have described the frequency of undiagnosed ankylosing 
spondylitis or spondyloarthritis, in settings that are comparable to Sweden. In 
a population-based study from Greece 2005(92) the prevalence of ankylosing 
spondylitis was estimated to be 0.24%, and the total prevalence of 
spondyloarthritis 0.49%. In this cohort 95% of the spondyloarthritis cases had 
sought medical care for their symptoms previously and only the remaining 
5% were diagnosed by the researchers during the study. Another study, 
comparing the consultation prevalence for musculoskeletal disorders in 
England and Sweden, found that only a small minority (3%) of patients with 
ankylosing spondylitis were exclusively treated in primary care (in the Skåne 
region in southern Sweden)(173). If the results from these two studies are 
possible to generalize to the general population of Sweden, this selection bias 
is unlikely to have a significant impact on the prevalence estimates. 
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Concerning the comparisons of length of formal education, there is also a risk 
of selection bias, if a shorter education increases the likelihood of being 
diagnosed with ankylosing spondylitis and receiving health care. For 
example, this could be true if a shorter formal education leads to a physical 
occupation where the symptoms of ankylosing spondylitis is more of a 
hindrance. But an alternative bias could also occur if subjects in higher 
socioeconomic groups chose private health care to a larger extent and thus 
are not detected through the national outpatient register. The proportion of 
patients with ankylosing spondylitis in Sweden, who are exclusively seen in 
private care is not known. However, based on unpublished data, from the 
Swedish Rheumatology Quality Register, only 4.6% of patients with 
ankylosing spondylitis receiving treatment with TNF-inhibitors are treated in 
private care, but it is difficult to assess the combined magnitude and direction 
of these possible biases more precisely in this cross-sectional study. 
Study III 
Since the comparisons between the study-groups only include the 48% of the 
subjects responding to the survey, there is an obvious risk of non-response 
bias, here acting as a selection bias. In order to asses this a comparison was 
made between responders and non-responders, where it was shown that the 
responders had a statistically significant higher proportion of chronic diseases 
(ankylosing spondylitis, psoriatic arthritis and undifferentiated spondylo-
arthritis), and anti-rheumatic treatment, compared to the non-responders, who 
had significantly more reactive arthritis. From this it can be deduced that the 
study subgroup called “other-spondyloarthritis” are more likely to be non-
responders, compared to the other two groups. The direction of the bias is 
likely to cause overestimations of the frequency of current inflammatory back 
pain, as well as of the self-reported disease burden and treatment in all three 
groups, but especially in the “other-spondyloarthritis” group. A comparison 
of the initial responders, with the responders after the first and second 
reminder may have given additional information on how the responders 
differed from the non-responders, but this was not performed.   
There is also a possibility of recall bias (information bias), if for example, the 
cases with ankylosing spondylitis are more likely to have paid notice to, or 
remember, the symptoms defining inflammatory back pain, compared to the 
other sub-groups. The possible types of bias in study III, which are difficult 
to quantify, reduces the external validity with regard to the prevalence of 
axial symptoms, whereas the internal validity of the comparison of patient 
reported outcome measures should be less compromised. 
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 Study IV and V 
In study IV and V, being case-control studies, selection bias would imply any 
systematic difference between the cases and controls, other than having 
ankylosing spondylitis, which would have been introduced during the 
selection process. This is not likely to occur. Possibly, there could be a 
selection bias in terms of severity of the disease (prevalence bias). If there 
was a large proportion of cases with ankylosing spondylitis with a less severe 
disease, who did not seek health care, or were only treated in primary care, 
and thus were not identified as cases, but this seems unlikely (see discussion 
under “Study II”).  
A similar problem arises from only including patients with ankylosing 
spondylitis as cases, if this is indeed only a radiographically more severe 
phenotype of all axial spondyloarthritis. If the associations with the analyzed 
exposures are, in turn, related to the severity of the disease, the resulting bias 
would then cause an overestimation of the differences between cases and 
controls. In both study IV and V sensitivity analyses were included, selecting 
presumably more severe subsets, with little effect on the point estimates.  
Misclassification should not introduce a bias in study IV and V, since there 
are no obvious reasons why the classification of exposures should differ 
between the cases and controls. The non-directional misclassification that 
remains will lower the efficiency of the studies, underestimating the 
differences between the groups, i.e. increasing the likelihood of making a 
type II error. 
6.2 Implications and future perspectives  
6.2.1 Prevalence and perceived health 
The prevalence of ankylosing spondylitis, determined in study II, is close to 
the prevalence estimates reported in other similar populations in Europe and 
North America. In particular, our base case prevalence of 0.18% was very 
similar to the weighted mean for Europe (0.186%) in a systematic review 
from 2014(76). If standardizing our crude prevalence based on age-groups 
and sex, using the European Standard Population 2013 (not presented in 
study II), it was 0.19%.  
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The consistency with previous estimates strengthens the validity of our 
methods for determining the prevalence on a national level in Sweden, 
although considering the high HLA-B27 prevalence in Sweden, perhaps an 
even higher prevalence could have been expected, compared to other parts of 
Europe. 
Figure 5. The point-prevalence of ankylosing spondylitis in Sweden, 31 December 
2009, stratified on sex and age-groups. 
When the prevalence was stratified on sex and age-groups (figure 5) it was 
apparent that the difference between men and women increased with age. It is 
possible that this is at least partly due to a previously inadequate recognition 
of the disease in women, which may have improved more recently. If 
ankylosing spondylitis is not seen as a separate disease entity, but rather a 
radiologically more severe expression of the whole group of axial 
spondyloarthritis, future studies of prevalence should also include the non-
radiographic forms, both in order to detect cases with an earlier disease but 
also to avoid bias based on severity and sex.  
Detection of axial disease and perceived health 
Using patient registers, based on ICD-codes, to identify non-radiographic 
axial spondyloarthritis is problematic, since the current ICD-classification 
system is not congruent with the evolving concept of axial spondyloarthritis. 
Patients with other axial spondyloarthritis diseases, apart from ankylosing 
spondylitis, cannot easily be identified in the register, and therefore 
additional data would be needed to confirm an axial manifestation. Features 
that could be used to support the existence of an axial disease in this setting, 
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includes imaging (MRI/radiographs), symptoms of inflammatory back pain, 
and limitations in spine motion.  
In study III, we combined spondyloarthritis diagnoses from the register, with 
self-reported symptoms of inflammatory back pain, with the purpose of 
identifying axial disease. However, only 43% of the patients with ankylosing 
spondylitis, who per definition have an axial disease, reported current 
inflammatory back pain, although previous studies have confirmed the 
validity of the diagnoses in the regional register. In fact, while 82% of the 
cases with ankylosing spondylitis reported having back pain during the last 
year, only 52% reported having it for more than three months, which is the 
entry criterion for both the Berlin and the ASAS definitions of inflammatory 
back pain and a clinical criterion in the modified New York criteria (although 
not specified as occurring in the last year). The relatively low frequency of 
chronic back pain among the responders may partly be a result of the patients 
receiving an adequate treatment, but this also illustrates the fact that axial 
symptoms are not constant in spondyloarthritis. Hence, using reported back 
pain of more than three months, in the preceding year, may not be sensitive 
for detecting axial disease in patients with spondyloarthritis.  
In “early disease” cohorts, of axial spondyloarthritis, inflammatory back pain 
is the most frequent symptom/sign(27), but it is also common in patients who 
do not fulfill the classification criteria for axial spondyloarthritis(79). The 
approach of using self-reported inflammatory back pain to detect axial 
disease, in patients with a spondyloarthritis diagnosis, has been used in other 
studies. In one study 2012(19), the prevalence of axial spondyloarthritis in 
the US (based on the NHANES-survey) was estimated using self-reported 
data. Another study(93), also based on the NHANES-survey, used self-
reported data to determine the prevalence of spondyloarthritis and 
inflammatory back pain in subject with psoriasis.  
The tree groups compared in study III reported similar levels of axial 
symptoms, based on the PROMs for spinal pain, BASDAI and BASFI, which 
may support the existence of axial disease. However, the PROMs used are 
not necessarily specific for axial spondyloarthritis, but may reflect pain or 
impairment related to other disorder as well. Other forms of chronic pain, 
such as fibromyalgia, frequently co-exists with axial spondyloarthritis, and 
differentiating this from an inflammatory axial disease is not straight 
forward(174). The prevalence of fibromyalgia in ankylosing spondylitis has 
been described as 4-15%(175, 176), although higher numbers have also been 
reported. A preliminary report has indicated that patients with fibromyalgia 
Ulf Lindström 
45 
do not falsely fulfil the ASAS-criteria for axial spondyloarthritis(177), but 
this needs to be replicated. 
Fibromyalgia will affect the scores of many of the frequently used outcome 
measures in axial spondyloarthritis. As an example, two studies of 
fibromyalgia in ankylosing spondylitis found that both the BASDAI and 
BASFI scores were strongly influenced (increased) by concurrent 
fibromyalgia(175, 176). In another recent (2016) study patients with both 
axial spondyloarthritis and fibromyalgia were compared with patients with 
only fibromyalgia, with regard to BASDAI and ASDAS, and were not 
statistically different, although the scores for BASDAI were if anything 
higher in the group with only fibromyalgia(178). Another study, comparing 
patients with psoriatic arthritis with patients with fibromyalgia, found no 
statistical difference in the frequency of inflammatory back pain (43.2% vs. 
35.8%) and a higher enthesitis score (Maastrich Ankylosing Spondylitis 
Enthesitis Score) in the fibromyalgia patients(179).  
 Using more objective biomarkers of inflammation to distinguish 
inflammatory back pain from non-inflammatory back pain in spondylo-
arthritis is tempting, but clinically widely used markers of inflammation such 
as the C-reactive protein are often normal in axial spondyloarthritis(10). 
Furthermore, MRI of the sacroiliac joints and the spine frequently reveal 
bone marrow edema congruent with the ASAS-criteria, both in patients with 
non-specific back pain and in healthy controls(180). There are also few 
studies examining the frequency of radiographic sacroiliitis in the normal 
population, but in the first NHANES study(181) (1971-1975), moderate or 
severe sacroiliitis was detected in 0.73% of men ages 25-74 years(182). 
However, only 54% of those with moderate or severe sacroiliitis, reported 
having received treatment for joint problems, and only 7.6% reported current 
significant low back pain(182). Several studies have also indicated a low to 
moderate reliability and reproducibility for radiographic assessment of 
sacroiliitis(183-185). Better methods/protocols for detection of axial 
spondyloarthritis are therefore needed. 
Future perspectives 
The ASAS-criteria for axial spondyloarthritis have a high sensitivity and 
specificity, but were constructed based on consecutive patients with chronic 
back pain included by rheumatologists(49). Further evaluation is needed to 
determine how they perform in detecting axial spondyloarthritis in a broader 
population setting.  
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To facilitate the use of health-care registers in epidemiological research, and 
health-care planning, an update of the axial spondyloarthritis concept in the 
ICD-classification system would be appropriate.  
Further population-based studies are also needed to verify the high 
frequencies of axial disease we found in other forms of spondyloarthritis than 
ankylosing spondylitis, and to find ways to better differentiate symptoms due 
to an axial disease from other types of chronic pain. The latter aspect could 
be addressed by including cohorts with other causes of chronic pain, such as 
fibromyalgia and degenerative back disease. 
Comments on age distribution of ankylosing spondylitis 
In study II we determined the prevalence in the age-groups 16-64 years, if we 
alternatively estimate the total (base case) prevalence in all age-groups it was 
0.21% (cases 20044/Swedish population 9.3 million on the 31 December 
2009). In a chronic disease, such as ankylosing spondylitis, the cumulative 
incidence up until a certain time-point, represents the point-prevalence at that 
time. Taking into account that ankylosing spondylitis is considered to start 
before the age of 30 years in 80% of the cases, and almost exclusively before 
the age of 45 years (21), the peak in prevalence in the age-groups 55-64 years 
(around 0.33%) can therefore be seen as an estimate of the proportion of the 
population, who over the whole lifetime is diagnosed with ankylosing 
spondylitis. 
 In the age-groups above 64 years (data not presented in study II) there was a 
gradual decline in prevalence. This is likely to, at least partly, be an artefact. 
The probability of ankylosing spondylitis being registered in the patient 
register can be expected to drop in the older age-groups, as other health-
problems over-shadow the rheumatic complaints, and it has also been 
suggested that the symptoms of axial disease may decrease in the 
elderly(186).  
Interestingly, several other studies have reported a similar decline in the 
prevalence of both HLA-B27 and ankylosing spondylitis, in specific older 
age-groups (75, 187). There are some data supporting an increased mortality 
for HLA-B27 carriers in some age-groups, even after adjusting for 
spondyloarthritis disease(188). One suggested explanation is that HLA-B27 
is associated with an increased susceptibility to particular childhood 
infections, more prevalent in specific time-periods, and thereby to a higher 
mortality early in life. This mechanism was proposed in the French 
GAZELLE study, as a possible explanation for a lower HLA-B27 prevalence 
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in age-groups older than 70-years (75). This would need to be replicated and 
investigated further. 
6.2.2  Predictors  
The role of non-genetic risk factors in ankylosing spondylitis are still largely 
unknown. In reactive arthritis, guttate psoriasis, and inflammatory bowel 
disease, the triggering infections are sometimes very conspicuous, and it is 
unlikely that a similar trigger for ankylosing spondylitis would have been 
over-looked. The fact that ankylosing spondylitis occurs worldwide, and 
roughly follows the prevalence of HLA-B27, suggests that any contributing 
environmental risk factors are likely to be ubiquitous. In the studies included 
in this thesis four parameters have been presented, that may be predictive or 
etiologically linked with ankylosing spondylitis: having a shorter formal 
education, having older siblings, and appendicitis and respiratory tract 
infections during childhood. 
In study II, not described previously, we found a higher prevalence of 
ankylosing spondylitis associated with fewer years of formal education. A 
higher prevalence related to a shorter formal education, used as a marker for 
lower socioeconomic status, has been described for many types of chronic 
diseases(189), such as rheumatoid arthritis(190), but it is not clear how this 
would apply to ankylosing spondylitis. As discussed in the previous section, 
several methodological explanations are possible, but it is also possible that a 
low level of education is a proxy for other exposures, such as smoking or 
occupation (mechanical stress) which affect the disease development. This 
needs to be investigated further.  
In study IV the only detected difference in characteristics at birth, between 
cases and controls, was the increased risk associated with having older 
siblings. Having older siblings is different from the other perinatal 
characteristics evaluated, such as birth weight or season of birth, in that it 
may be a proxy for exposure to infections during an extended period of time 
in early childhood, while the other characteristics rather represent a 
phenotype at the time of birth, or reflect the intrauterine conditions.  
In study V the negative association with appendicitis was stronger in the 
group having had the procedure before the age of 13 years, compared to 13-
16 years, suggesting a more prominent impact early in life, compared to later 
in childhood. Acute appendicitis is currently regarded as triggered primarily 
by infections, although a genetic component is also present(191). One 
previously proposed mechanism for HLA-B27’s association with ankylosing 
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spondylitis is that it affects the composition of the gut-flora(192). Very sparse 
data have indicated that HLA-B27-status is not linked to differences in 
microbial composition of the gut, in patients with established 
spondyloarthritis(145), but further studies are needed to explore this, and if 
HLA-B27 may be associated with appendicitis. 
Since, ankylosing spondylitis is not a mono-genetic disease, it is possible that 
differences in genetic predisposition may also cause differences in 
susceptibility to exposure to non-genetic risk factors. Future studies should 
therefore aim to include data on known genetic risk factors, as a minimum 
HLA-B27-status, and preferably also data on familiar occurrence of 
ankylosing spondylitis. Future studies, on non-genetic risk factors for 
ankylosing spondylitis, may focus on smoking (including maternal smoking 
during pregnancy and passive smoking during childhood); mechanical stress, 
trauma, occupation and other socioeconomic aspects, as well as a wider 
spectrum of microbial exposures.   
Future perspectives  
In studies of environmental exposures, in axial spondyloarthritis, ideally it 
should be possible to pin-point the time of disease onset. Unfortunately, 
disease onset is poorly defined in spondyloarthritis, and it is unknown what 
time elapses between the initiation of the underlying disease mechanisms and 
the first symptoms. In cohort-studies of early axial spondyloarthritis, such as 
the SPACE(79) and the DISIRE(193) (back pain less than two and three 
years, respectively), a substantial proportion of the patients already have 
inflammatory co-morbidities and radiographic pathology at inclusion, 
suggesting that by the time such patients are identified and included in 
studies they already have a well-established disease. Using such “early 
disease” cohorts to identify predisposing exposures might therefore not be the 
best solution. 
The many similarities between reactive arthritis and other spondyloarthritis 
subtypes (such as oligo arthritis, enthesitis, dactylitis, sacroiliitis(101), HLA-
B27(130), and response to treatment(99)) may support the use of reactive 
arthritis as a model for early spondyloarthritis overall. Most cases with 
reactive arthritis start as a sub-acute peripheral oligo arthritis. Assuming that 
the disease onset occurs at the same time that the symptoms start, this could 
present an opportunity to study disease mechanisms in a very early (days-
weeks?) phase of spondyloarthritis. This could be done by including incident 
cases prospectively at a referral center, providing that the delay between the 
patients´ first contact with health care (primary care or emergency unit) could 
be minimized. This type of study is obviously not suited for studying specific 
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triggering factor for ankylosing spondylitis, but it could be used to investigate 
the early immune phenotype (e.g. expansion of inflammatory cells, such as 
innate lymphoid cells (194)), and how the course of the arthritis relates to 
parameters such as intestinal inflammation and normalization of gut 
microbiota (after enteritis). 
Case-control studies have an advantage if the outcome is rare and may be 
more cost-effective, compared to cohort studies. However, if the data on 
exposures are collected retrospectively, e.g. through surveys, there is a 
considerable risk for recall bias, especially in spondyloarthritis where both 
the time of disease onset and the time of the exposures are poorly 
characterized. Another example where the case-control setup is limited, is if 
the data on exposures are identified after the disease onset, e.g. serological 
markers for Klebsiella, where this may prevent causal inference. Using a 
nested case-control design, analyzing existing data already collected 
prospectively, such as the register data on exposures in study IV and V, may 
be more reliable in that aspect, since it eliminates the risk of recall bias, and 
establishes a temporal order. Limitations with using register data, not 
originally collected for research purposes, includes misclassification and 
restrictions in how precisely the exposures can be defined. Retrospective 
cohort studies, using register data, would have similar limitations. Some 
regional registers in Sweden (such as the Skåne Health Care Register) also 
includes primary care, which would allow for a more complete analysis of 
some exposures, such as infections, trauma and perhaps smoking. Case-
control studies may also be suitable for assessing the effect of maternal 
smoking and passive smoking during childhood, if reliable data sources can 
be identified for such exposures. 
Prospective cohort studies investigating multiple potential exposures, with 
the rare out-come of developing axial spondyloarthritis, would need to be 
very large, and thus very expensive. A potential solution may be to tap into 
an existing prospective cohort, such as the DiPiS/TEDDY birth cohort 
study(195), and collect complementary data on exposures and outcome from 
additional sources, such as registers. Using axial spondyloarthritis (or 
ankylosing spondylitis) as the outcome in such a study would necessitate an 
observation period of several decades, in order for the disease to develop. But 
other hypotheses could be tested earlier, such as the effect of HLA-B27 on 
the spectrum of childhood infections.  
Previous studies on the composition of the early gut microbiome (Bäckhed 
2015(196)) have described how the gut flora develops during the first year. 
Such cohorts, or similar, could be complemented by data on HLA-B27-status 
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and occurrence of spondyloarthritis in the family, to assess whether this 
affects the composition. 
The Swedish twin-studies (197, 198), include twins born since 1954. Using 
existing twin-cohorts like these may also be a good alternative, when 
studying environmental risk factors, in particular if HLA-B27 status is 
known. The advantage of twin studies is that it gives a good opportunity to 
assess the effect of the familial risk contra non-genetic factors. Similar 
benefits could also be gained from using the Swedish multi-generation 
register(199). If combined with national or regional registers, the association 
with both childhood infections, smoking and perhaps occupation, could be 
explored further.  
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7 CONCLUSIONS 
 
The diagnoses of ankylosing spondylitis and undifferentiated spondylo-
arthritis in the Swedish national patient register were determined to have a 
high validity, but the register could not be used to identify incident cases. 
The point-prevalence of ankylosing spondylitis in Sweden, in 2009, was 
0.14% or 0.18%, depending on the case-definition, with a higher prevalence 
in northern Sweden, compared to the southern parts, and a higher prevalence 
associated with fewer years of formal education. The prevalence increased 
linearly up to the age of 55 years, and then plateaued. 64% were men, and 
there were differences between men and women, both with regard to clinical 
manifestations and pharmacological treatment. 
Current inflammatory back pain was common across the three subtypes of 
spondyloarthritis analyzed (43% of ankylosing spondylitis, 31% of psoriatic 
arthritis and 39% of other spondyloarthritis) and the groups, with current 
inflammatory back pain, reported similar levels of disease activity. 
Having older siblings was associated with an increased risk for later 
development of ankylosing spondylitis (odds ratio 1.23; 95% confidence 
interval 1.09 to 1.39), while birth weight and season of birth were not. 
Hospitalization with infections overall, or with enteric infections or 
urogenital infections, during childhood were not associated with later 
development of ankylosing spondylitis. Instead, respiratory tract infections 
(odds ratio 1.24; 95% confidence interval 1.07 to 1.44) and in particular with 
tonsillitis (odds ratio 1.31; 95% confidence interval 1.03 to 1.67), were 
associated with an increased risk for development of ankylosing spondylitis, 
and appendicitis with a decreased risk (odds ratio 0.59; 95% confidence 
interval 0.41 to 0.83).  
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